The Hepatitis C Market: Biotech’s Version of the Daytona 500

[willbb]

Many, many players in the multi -billion dollar quest for HCV cure.


http://hepatitiscresearchandnewsupdates.blogspot.com/2011/12/hepatitis-c-market-biotechs-version-of.html


Biotech rivalries are sometimes a bit like boxing matches, where you have two lone fighters vying for the prize. But the hepatitis C market is turning into a battle royal that’s more wide open and unpredictable, with all the competitive maneuvering, surprise crashes, and comebacks you might expect from the Daytona 500.

The medical advances in hepatitis C have been dizzying this year, especially in what it means in terms of multi-billion dollar business implications. The safest thing to say is that there’s plenty of good news for patients this year, but that shareholders in the major hepatitis C drug developers had better hold on tight as a new standard of care gets established.

[spectda]

Lucy, lol - it's my keyboard, really :)

[spectda]

Sadly the money drives the research. Great for people with HCV in my opinion, really unfortunate for people who have diseases that are rare. I guess we are lucy in some strange way.